|
Volumn 14, Issue SUPPL. 2, 2000, Pages 29-38
|
Pharmacoeconomic analysis of HBV liver transplant therapies
|
Author keywords
HBlg; Hepatitis B; Insurance; Liver; Pharmacoeconomics; Transplantation
|
Indexed keywords
HEPATITIS B ANTIBODY;
HEPATITIS B SURFACE ANTIBODY;
HEPATITIS B SURFACE ANTIGEN;
HEPATITIS B(E) ANTIGEN;
LAMIVUDINE;
NUCLEOSIDE ANALOG;
VIRUS DNA;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL PROTOCOL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DOSE RESPONSE;
DRUG COST;
DRUG HALF LIFE;
DRUG MEGADOSE;
ECONOMIC ASPECT;
GRAFT INFECTION;
HEPATITIS B;
HEPATITIS B VIRUS;
HUMAN;
INFECTION CONTROL;
LIVER TRANSPLANTATION;
MAINTENANCE THERAPY;
MORTALITY;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ANTIVIRAL AGENTS;
COST CONTROL;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
ECONOMICS, PHARMACEUTICAL;
HEPATITIS B;
HEPATITIS B VIRUS;
HOSPITAL CHARGES;
HOSPITAL COSTS;
HUMANS;
IMMUNIZATION, PASSIVE;
IMMUNOGLOBULINS;
LIVER TRANSPLANTATION;
PURCHASING, HOSPITAL;
SAFETY;
SURVIVAL RATE;
TIME FACTORS;
TRANSPLANTATION, HOMOLOGOUS;
TREATMENT OUTCOME;
|
EID: 0033852099
PISSN: 09020063
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (19)
|
References (25)
|